Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.

Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.

Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.

Abstract: A method and a test for detecting coagulation activation, in particular when it is responsible for thromboembolic venous diseases; employs assaying D-dimers and assaying the soluble fibrin produced during a fibrinolysis process activated in a blood sample. The method of the invention pertains to comparing the level of D-dimers corresponding to degradation of soluble fibrin and the level of D-dimers of the sample with normal threshold values. The test of the invention may also be used to determine whether anti-coagulation is sufficient in a patient.

Abstract: The present invention relates to an isolated cell capable of fixing tumour cells, expressing the CD10 protein and expressing at least one MDR protein, and to the use of this cell for screening for anti-tumour compounds.

Abstract: A method and a test for detecting coagulation activation, in particular when it is responsible for thromboembolic venous diseases; employs assaying D-dimers and assaying the soluble fibrin produced during a fibrinolysis process activated in a blood sample. The method of the invention pertains to comparing the level of D-dimers corresponding to degradation of soluble fibrin and the level of D-dimers of the sample with normal threshold values. The test of the invention may also be used to determine whether anti-coagulation is sufficient in a patient.

Abstract: The present invention relates to gene therapy for the treatment of tumors. The invention more particularly relates to introduction of a gene encoding an anti-angiogenic factor into cells of a tumor, for example with a defective adenovirus vector, to inhibit growth or metastasis, or both, of the tumor. In a specific embodiment, delivery of a defective adenovirus that expresses the amino terminal fragment of urokinase (ATF) inhibited growth and metastasis of tumors. These effects were correlated with a remarkable inhibition of neovascularization within, and at the immediate vicinity of, the injection site. Delivery of a defective adenovirus vector that expresses kringles 1 to 3 of angiostatin inhibited tumor growth and tumorigenicity, and induced apoptosis of tumor cells. The invention further provides viral vectors for use in the methods of the invention.

Abstract: The present invention relates to gene therapy for the treatment of tumors. The invention more particularly relates to introduction of a gene encoding an anti-angiogenic factor into cells of a tumor, for example with a defective adenovirus vector, to inhibit growth or metastasis, or both, of the tumor. In a specific embodiment, delivery of a defective adenovirus that expresses the amino terminal fragment of urokinase (ATF) inhibited growth and metastasis of tumors. These effects were correlated with a remarkable inhibition of neovascularization within, and at the immediate vicinity of, the injection site. Delivery of a defective adenovirus vector that expresses kringles 1 to 3 of angiostatin inhibited tumor growth and tumorigenicity, and induced apoptosis of tumor cells. The invention further provides viral vectors for use in the methods of the invention.

Abstract: The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.